SHORE REGIONAL CANCER CENTER
AVAILABLE PROTOCOLS

As of March 13, 2008

Less than 10% of adult cancer patients participate in clinical trials

Breast:

CALGB 40302

Endocrine Therapy With or Without Inhibition of EGF and HER2 Growh Factor Receptors: A Randomized, Double Blind, Placebo-Controlled Phase III Trial of Fulvestrant With or Without Lapatinib (GW572016) for postmenopausal Women with Hormone Receptor positive advanced Breast Cancer+

N063D/BIG-2-06

ALTOO - Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Study - A randomized, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer

NSABP B-39/RTOG 0413

A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer

NSABP B-42

A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor(AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Cancer

PAACT I

Program for the Assessment of Clinical Cancer Tests - Trial Assigning Individualized Options for Treatment: The TAILORx Trial

SWOG S0307

Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer

ACOSOG Z1031

A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25mg daily), Letrozole (2.5 mg), or Anastrozole (1mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

ECOG E1105

A Randomized Phase III Double-Blind Placebo-Controlled Trial of First-line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-expressing Metastatic Breast Cancer

ECOG E5103

A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

Gynecological

GOG-0209

A Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF versus Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer

GOG-0218

A Phase III Trial of Carboplatin and Paclitaxel plus Placebo vs. Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, vs. Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III (suboptimal) and all Stage IV Epithelial Ovarian and Primary Peritoneal Cancer

Prostate:

RTOG 0534

A Phase III Trial Of Short Term Androgen Deprivation With Pelvic Lymph Node Or Prostate Bed Only Radiotherapy (SPORT) In Prostate Cancer Patients With A Rising PSA After Radical Prostatectomy

S0421

Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo For Patients with Advanced Hormone Refractory Prostate Cancer

CALGB 90202

A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone

Colon:

ECOG E5202

A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers

SWOG S0600

Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab with or without Bevacizumab as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with either FOLFOX, OPTIMOX, or XELOX

CALGB 80405

A Phase III Trial of Irinotecan/f-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Rectal

ECOG E5204

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation

Kidney:

ECOG E2805

A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma

Gastric or Gastroesophageal

CALBG 80101

Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma

CALBG 80403

Randomized Phase II Study of ECF-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer